Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSPA9 | P38646 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742500 | 0.85 | ALOX5 (0.41) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL19742586 | 0.83 | — | — | |
| SCHEMBL19742659 | 0.82 | AKR1B1 (0.39) | CYP1A2AKR1B1MAPTALDH1A1KMT2A | |
| SCHEMBL19742509 | 0.79 | KMT2A (0.35) | CYP1A2AKR1B1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL29352631 | 0.79 | KMT2A (0.35) | CYP1A2AKR1B1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL30279968 | 0.79 | KMT2A (0.35) | CYP1A2AKR1B1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL19742727 | 0.78 | TDP1 (0.36) | CYP1A2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL30279937 | 0.78 | TDP1 (0.36) | CYP1A2MAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL19742671 | 0.77 | NPBWR1 (0.38) | MAPTALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL19742602 | 0.76 | ALDH1A1 (0.39) | CYP1A2MAPTALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474855-B1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3474855-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Polaris Pharmaceuticals, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | POLARIS PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2017223432-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | POLARIS PHARMACEUTICALS | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369489-A1 | CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF | CSNK1A1, CSNK2A1, CSNK2A3 | CYP1A2 3115/4885AKR1B1 918/4885MAPT 543/4885 |
| US-10227344-B2 | CK2 inhibitors, compositions and methods thereof | CSNK1A1, CSNK2A1, CSNK2A3 | CYP1A2 3115/4885AKR1B1 918/4885MAPT 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.